CoChat

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

Open access
Ridker, Paul M · 2021 · Cardiovascular Research
Cited by 156

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Over the past 40 years, the most successful pharmacologic approach to cardiovascular disease prevention has been aggressive lowering of LDL cholesterol. Yet, cardiologists and vascular biologists now have hard evidence that inhibition of the NLRP3 to IL-1β to IL-6 to C-reactive protein (CRP) pathway of innate immunity is also a potent target for atheroprotection.1 This proof-of-principle derives from the 10 000 participant multi-national CANTOS trial presented in 2017 in which a monoclonal antibody targeting IL-1β significantly reduced recurrent major adverse cardiovascular events by 15–17%2 with the benefit directly related to the magnitude of reduction in downstream IL-6 and CRP.3,4 Of considerable importance, the clinical benefit observed within CANTOS was of the same magnitude as that observed in trials of PCSK9 inhibition, yet was achieved in the absence of any reduction in LDL cholesterol. Directly targeting IL-6 itself has thus rapidly become a priority for the atherosclerosis research community.5 This hypothesis has garnered considerable support from Mendelian randomization studies which suggest that genetic variants in the IL-6 signalling pathway associate with lifelong coronary risk,6,7 from phenome-wide association studies implicating IL-6 in multiple forms of atherosclerotic disease,8 and from murine models in which genetically modified mice with high IL-6 levels show increased susceptibility to atherogenesis yet also demonstrate fewer plaque lesions when pre-treated with an anti-mouse IL-6 receptor antagonist.9 All of these findings, and others, support the likelihood that lowering IL-6 activity will reduce incidence rates not just of myocardial infarction and stroke, but also of abdominal aortic aneurysm, post-PCI complications, and perhaps peripheral arterial disease. Other data implicate the IL-1β to IL-6 pathway in congestive heart failure10 and acute coronary ischaemia.11 Despite this promise, the safety and efficacy of IL-6 inhibition among individuals at high atherosclerotic risk have been uncertain. The recent phase II RESCUE trial addressed this issue with ziltivekimab, a fully human monoclonal antibody directed against the IL-6 ligand and that is being specifically developed for atherothrombotic disease.12 RESCUE focused on individuals with elevated levels of high-sensitivity C-reactive protein (hsCRP) and chronic kidney disease (CKD), a group with substantial cardiovascular risk and unmet clinical need for whom alternative proven anti-inflammatory agents such as renally excreted colchicine are contraindicated. IL-6 levels are also a powerful predictor of incident vascular disease in the setting of CKD, more so in fact than LDL cholesterol.13 In brief, the RESCUE investigators randomly allocated 264 patients with residual inflammatory risk (hsCRP >2 mg/L) and Stages 3–5 CKD to subcutaneous administration of placebo or to ziltivekimab 7.5 mg, 15 mg, of 30 mg once every 4 weeks over a 24-week period. Overall, the trial primary endpoint of median hsCRP change over time were −77%, −88%, and −92% across the ascending ziltivekimab dose range as compared to −4% on placebo (all P-values <0.0001). (Figure 1) Thus, the magnitude of hsCRP reduction in RESCUE was roughly twice as large as that achieved within CANTOS using an upstream IL-1β inhibitor. Moreover, compared to placebo, waterfall plots demonstrate highly efficient inhibition of IL-6 and subsequent hsCRP reductions with ziltivekimab for virtually all randomized participants. These findings suggest that direct IL-6 inhibition may reduce the wide individual variation previously seen with IL-1β inhibition. In parallel with the primary hsCRP data, comparable dose-dependent reductions for fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein(a) were also observed. The observation that ziltivekimab reduced lipoprotein(a) is consistent with evidence that IL-6 induces LPA mRNA expression in human hepatocytes, possibly providing another mechanism for benefit.14 Finally, ziltivekimab did not increase atherogenic lipid levels and was without serious injection site reactions, sustained thrombocytopenia or neutropenia, at least over the 24-week trial period. These safety data, if confirmed in larger long-term trials, raise the possibility that ziltivekimab may be unique among commercially available IL-6 inhibitors. Primary results of the RESCUE Trial of IL-6 inhibition with ziltivekimab on hsCRP. (A) Median percent change in hsCRP with ascending doses of ziltivekimab; (B) Time dependent effects of ziltivekimab over the 24 week treatment period followed by an 8 week washout period; (C) Waterfall plots for individual trial participants showing minimal variability for hsCRP reduction particularly at the 15 and 30 mg doses of ziltivekimab. Data are shown in black for placebo, red for ziltivekimab 7.5 mg, blue for ziltivekimab 15 mg, and green for ziltivekimab 30 mg, all given subcutaneously once monthly. Primary results o

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvab231

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 156

Metadata

Authors
Ridker, P. M.
Venue
Cardiovascular Research
Published
2021-08-05
Volume
117
Issue
11
Pages
e138-e140
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W3193271138
Cited by
156
References
4
FWCI
16.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.